Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

Immunity

Volumn 38, Issue 1, 2013, Pages 176-186

  Liao, Hua Xin ^a   Bonsignori, Mattia ^a   Alam, S Munir ^a   McLellan, Jason S ^b   Tomaras, Georgia D ^a   Moody, M Anthony ^a   Kozink, Daniel M ^a   Hwang, Kwan Ki ^a   Chen, Xi ^a   Tsao, Chun Yen ^a   Liu, Pinghuang ^a   Lu, Xiaozhi ^a   Parks, Robert J ^a   Montefiori, David C ^a   Ferrari, Guido ^a   Pollara, Justin ^a   Rao, Mangala ^c   Peachman, Kristina K ^c   Santra, Sampa ^d   Letvin, Norman L ^d   Karasavvas, Nicos ^e   Yang, Zhi Yong ^b   Dai, Kaifan ^b   Pancera, Marie ^b   Gorman, Jason ^b   Wiehe, Kevin ^a   Nicely, Nathan I ^a   Rerks Ngarm, Supachai ^f   Nitayaphan, Sorachai ^e   Kaewkungwal, Jaranit ^g   Pitisuttithum, Punnee ^h   Tartaglia, James ⁱ   Sinangil, Faruk ^j   Kim, Jerome H ^c   Michael, Nelson L ^c   Kepler, Thomas B ^k   Kwong, Peter D ^b   Mascola, John R ^b   Nabel, Gary J ^b   Pinter, Abraham ^l   Zolla Pazner, Susan ^m,n   Haynes, Barton F ^a   more..

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^f MINISTRY OF PUBLIC HEALTH   (Thailand)

^g MAHIDOL UNIVERSITY   (Thailand)

^h MAHIDOL UNIVERSITY   (Thailand)

ⁱ SANOFI PASTEUR   (France)

^j Global Solutions for Infectious Diseases   (United States)

^k BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^m VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁿ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN GP70; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RV 144 VACCINE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CONCENTRATION RESPONSE; CONFORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CRYSTAL STRUCTURE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOREACTIVITY; INFECTION RISK; MEMORY CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; VIRION; VIRUS REPLICATION; VIRUS STRAIN;

AIDS VACCINES; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBODIES, MONOCLONAL; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN BINDING; PROTEIN CONFORMATION;

EID: 84872809067     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2012.11.011     Document Type: Article

References (46)

1. Adams P.D., Grosse-Kunstleve R.W., Hung L.W., Loerger T.R., McCoy A.J., Moriarty N.W., Read R.J., Sacchettini J.C., Sauter N.K., Terwilliger T.C. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D Biol. Crystallogr. 2002, 58:1948-1954.
2. Alam S.M., McAdams M., Boren D., Rak M., Scearce R.M., Gao F., Camacho Z.T., Gewirth D., Kelsoe G., Chen P., Haynes B.F. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol. 2007, 178:4424-4435.
3. Alam S.M., Scearce R.M., Parks R.J., Plonk K., Plonk S.G., Sutherland L.L., Gorny M.K., Zolla-Pazner S., Vanleeuwen S., Moody M.A., et al. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J. Virol. 2008, 82:115-125.
4. Alam S.M., Liao H.X., Dennison S.M., Jaeger F., Parks R., Anasti K., Foulger A., Donathan M., Lucas J., Verkoczy L., et al. Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation. J. Virol. 2011, 85:11725-11731.
5. Alam S.M., Liao H.X., Tomaras G.D., Bonsignori M., Tsao C.Y., Hwang K.K., Chen H., Lloyd K.E., Bowman C., Sutherland L., et al. Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J. Virol. 2012, Published online November 21, 2012. 10.1128/JVI.00718-12.
6. Arthos J., Cicala C., Martinelli E., Macleod K., Van Ryk D., Wei D., Xiao Z., Veenstra T.D., Conrad T.P., Lempicki R.A., et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat. Immunol. 2008, 9:301-309.
7. Bonsignori M., Moody M.A., Parks R.J., Holl T.M., Kelsoe G., Hicks C.B., Vandergrift N., Tomaras G.D., Haynes B.F. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J. Immunol. 2009, 183:2708-2717.
8. Bonsignori M., Hwang K.K., Chen X., Tsao C.Y., Morris L., Gray E., Marshall D.J., Crump J.A., Kapiga S.H., Sam N.E., et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 2011, 85:9998-10009.
9. Bonsignori M., Pollara J., Moody M.A., Alpert M.D., Chen X., Hwang K.K., Gilbert P.B., Huang Y., Gurley T.C., Kozink D.M., et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 2012, 86:11521-11532.
10. Burrer R., Haessig-Einius S., Aubertin A.M., Moog C. Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41. Virology 2005, 333:102-113.
11. Doria-Rose N.A., Georgiev I., O'Dell S., Chuang G.Y., Staupe R.P., McLellan J.S., Gorman J., Pancera M., Bonsignori M., Haynes B.F., et al. A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J. Virol. 2012, 86:8319-8323.
12. Edmonds T.G., Ding H., Yuan X., Wei Q., Smith K.S., Conway J.A., Wieczorek L., Brown B., Polonis V., West J.T., et al. Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 2010, 408:1-13.
13. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 2004, 60:2126-2132.
14. Ferrari G., Pollara J., Kozink D., Harms T., Drinker M., Freel S., Moody M.A., Alam S.M., Tomaras G.D., Ochsenbauer C., et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J. Virol. 2011, 85:7029-7036.
15. Gorny M.K., Moore J.P., Conley A.J., Karwowska S., Sodroski J., Williams C., Burda S., Boots L.J., Zolla-Pazner S. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J. Virol. 1994, 68:8312-8320.
16. Gorny M.K., Pan R., Williams C., Wang X.H., Volsky B., O'Neal T., Spurrier B., Sampson J.M., Li L., Seaman M.S., et al. Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. Virology 2012, 427:198-207.
17. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., Evans D.T., Montefiori D.C., Karnasuta C., Sutthent R., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 2012, 366:1275-1286.
18. Haynes B.F., Kelsoe G., Harrison S.C., Kepler T.B. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 2012, 30:423-433.
19. Karasavvas N., Billings E., Rao M., Williams C., Zolla-Pazner S., Bailer R.T., Koup R.A., Madnote S., Arworn D., Shen X., et al. The Thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res. Hum. Retroviruses 2012, 28:1444-1457.
20. Karlsson Hedestam G.B., Fouchier R.A., Phogat S., Burton D.R., Sodroski J., Wyatt R.T. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat. Rev. Microbiol. 2008, 6:143-155.
21. Keele B.F., Giorgi E.E., Salazar-Gonzalez J.F., Decker J.M., Pham K.T., Salazar M.G., Sun C., Grayson T., Wang S., Li H., et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 2008, 105:7552-7557.
22. Langer G., Cohen S.X., Lamzin V.S., Perrakis A. Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7. Nat. Protoc. 2008, 3:1171-1179.
23. Leaman D.P., Kinkead H., Zwick M.B. In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1. J. Virol. 2010, 84:3382-3395.
24. Leaver-Fay A., Tyka M., Lewis S.M., Lange O.F., Thompson J., Jacak R., Kaufman K., Renfrew P.D., Smith C.A., Sheffler W., et al. ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol. 2011, 487:545-574.
25. Liao H.X., Sutherland L.L., Xia S.M., Brock M.E., Scearce R.M., Vanleeuwen S., Alam S.M., McAdams M., Weaver E.A., Camacho Z., et al. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 2006, 353:268-282.
26. Liao H.X., Levesque M.C., Nagel A., Dixon A., Zhang R., Walter E., Parks R., Whitesides J., Marshall D.J., Hwang K.K., et al. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J. Virol. Methods 2009, 158:171-179.
27. Liao H.X., Chen X., Munshaw S., Zhang R., Marshall D.J., Vandergrift N., Whitesides J.F., Lu X., Yu J.S., Hwang K.K., et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J. Exp. Med. 2011, 208:2237-2249.
28. Liu P., Overman R.G., Yates N.L., Alam S.M., Vandergrift N., Chen Y., Graw F., Freel S.A., Kappes J.C., Ochsenbauer C., et al. Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. J. Virol. 2011, 85:11196-11207.
29. Ma B.J., Alam S.M., Go E.P., Lu X., Desaire H., Tomaras G.D., Bowman C., Sutherland L.L., Scearce R.M., Santra S., et al. Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog. 2011, 7:e1002200.
30. McLellan J.S., Pancera M., Carrico C., Gorman J., Julien J.P., Khayat R., Louder R., Pejchal R., Sastry M., Dai K., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480:336-343.
31. Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. 2005, Chapter 12. Unit 12.11.
32. Montefiori D.C., Karnasuta C., Huang Y., Ahmed H., Gilbert P., de Souza M.S., McLinden R., Tovanabutra S., Laurence-Chenine A., Sanders-Buell E., et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 2012, 206:431-441.
33. Moody M.A., Yates N.L., Amos J.D., Drinker M.S., Eudailey J.A., Gurley T.C., Marshall D.J., Whitesides J.F., Chen X., Foulger A., et al. HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. J. Virol. 2012, 86:7496-7507.
34. Nawaz F., Cicala C., Van Ryk D., Block K.E., Jelicic K., McNally J.P., Ogundare O., Pascuccio M., Patel N., Wei D., et al. The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission. PLoS Pathog. 2011, 7:e1001301.
35. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276:307-326.
36. Pancera M., McLellan J.S., Wu X., Zhu J., Changela A., Schmidt S.D., Yang Y., Zhou T., Phogat S., Mascola J.R., Kwong P.D. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J. Virol. 2010, 84:8098-8110.
37. Pinter A., Honnen W.J., Kayman S.C., Trochev O., Wu Z. Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Vaccine 1998, 16:1803-1811.
38. Plotkin S.A., Gilbert P.B. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. 2012, 54:1615-1617.
39. Pollara J., Hart L., Brewer F., Pickeral J., Packard B.Z., Hoxie J.A., Komoriya A., Ochsenbauer C., Kappes J.C., Roederer M., et al. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A 2011, 79:603-612.
40. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361:2209-2220. MOPH-TAVEG Investigators.
41. Rolland M., Tovanabutra S., deCamp A.C., Frahm N., Gilbert P.B., Sanders-Buell E., Heath L., Magaret C.A., Bose M., Bradfield A., et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat. Med. 2011, 17:366-371.
42. Rolland M., Edlefsen P.T., Larsen B.B., Tovanabutra S., Sanders-Buell E., Hertz T., deCamp A.C., Carrico C., Menis S., Magaret C.A., et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012, 490:417-420.
43. Seaman M.S., Janes H., Hawkins N., Grandpre L.E., Devoy C., Giri A., Coffey R.T., Harris L., Wood B., Daniels M.G., et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 2010, 84:1439-1452.
44. Trkola A., Matthews J., Gordon C., Ketas T., Moore J.P. A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J. Virol. 1999, 73:8966-8974.
45. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289. Protocol G Principal Investigators.
46. Zolla-Pazner S., Cardozo T. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat. Rev. Immunol. 2010, 10:527-535.